Deulumateperone

Deulumateperone (INNTooltip International Nonproprietary Name; developmental code name ITI-1284) is an experimental antipsychotic of the pyridopyrroloquinoxaline and butyrophenone families as well as a deuterated analogue of lumateperone which is under development as a sublingually administered orally disintegrating tablet (ODT) for the treatment of psychotic disorders, agitation, and generalized anxiety disorder.^[2][3][4][1] No recent development has been reported for treatment of depressive disorders, behavioral disorders, and dementia.^[2] It is being developed by Intra-Cellular Therapies.^[2][3][1] As of January 2025, it has reached phase 2 clinical trials.^[2][3]

Deulumateperone

Clinical data
Other names	Lumateperone deuterated; Deuterated lumateperone; ITI-1284; ITI1284; ITI-1284-ODT-SL
Routes of administration	Sublingual (orally disintegrating tablet)[1]
Drug class	Atypical antipsychotic
Identifiers
IUPAC name 1-(4-fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-(2-2H)hexahydro(2-2H)-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]butan-1-one
CAS Number	2102683-75-8
PubChem CID	140916642
UNII	NBA7J58PPP
Chemical and physical data
Formula	C24H26D2FN3O
Molar mass	395.518 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C([2H])([2H])CN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
InChI InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1/i14D2 Key:HOIIHACBCFLJET-FTHFLAHXSA-N

See also

• Pyridopyrroloquinoxaline
• List of investigational antipsychotics
• List of investigational antidepressants
• List of investigational anxiolytics
• List of investigational agitation drugs